Rabies immunoglobulin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Parenteral
Postexposure prophylaxis of rabies
Adult: In conjunction with rabies vaccine in unvaccinated individuals: As human rabies immunoglobulin (HRIG): 20 IU/kg. As equine rabies immunoglobulin (ERIG): 40 IU/kg. Administer as a single dose on the 1st day of rabies vaccine (or within 7 days after) via infiltration into and around the cleansed wound. If infiltration of the whole volume is not possible, any remaining dose may be injected intramuscularly in the deltoid muscle of the upper arm or anterolateral thigh (distant from the site of rabies vaccine administration).
Child: Same as adult dose.
Chống chỉ định
Hypersensitivity.
Thận trọng
Patients with IgA deficiency, bleeding disorders (e.g. thrombocytopenia) or those who are at risk of thrombosis (e.g. prolonged immobilisation, history of thrombosis, hyperviscosity syndrome). Children. Pregnancy and lactation.
Phản ứng phụ
Significant: Haemolysis, bleeding, haematoma, fever; injection site reactions (e.g. swelling, pain, erythema, warmth).
Cardiac disorders: Tachycardia.
Gastrointestinal disorders: Nausea and vomiting.
General disorders and administration site conditions: Fatigue, malaise, influenza like illness.
Musculoskeletal and connective tissue disorders: Chills, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria.
Potentially Fatal: Rarely, severe hypersensitivity reactions (e.g. anaphylactic shock).
IM/Parenteral: C
MonitoringParameters
Perform skin testing prior to administration of ERIG.
Tương tác
May interfere with immune response to live attenuated virus vaccines. Immunosuppresive agents (e.g. alkylating agents, metabolites, corticosteroids, radiation) may increase risk of rabies infection due to decrease in antibody response to postexposure prophylaxis. Increased risk of bleeding with anticoagulants.
Lab Interference
May cause false-positive results in serological tests.
Tác dụng
Description: Rabies immunoglobulin (RIG) is used for passive immunisation for individuals who are exposed to rabies virus and who have not been vaccinated against rabies. It provides immediate, temporary virus-neutralising antibodies until response to active immunisation with rabies vaccine is achieved. There are 2 kinds of rabies immunoglobulin based on their sources: human rabies immunoglobulin (HRIG) and highly purified equine rabies immunoglobulin (ERIG).
Pharmacokinetics:
Absorption: Absorbed slowly after IM administration.
Excretion: Serum half-life: Approx 21 days (IM).
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
Phân loại ATC
J06BB05 - rabies immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
References
Anon. Rabies Immune Globulin (Human). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/11/2018.

Anon. Rabies Immune Globulin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 08/11/2018.

Buckingham R (ed). Rabies Immunoglobulins. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2018.

Hyperrab (Grifols USA, LLC.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2018.

Joint Formulary Committee. Rabies Immunoglobulin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2018.

Rabies Vaccines and Immunoglobulins: WHO Position. World Health Organization. http://www.who.int/. Accessed 09/11/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Rabies immunoglobulin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in